Clinical Trial Search

Primary: Measurement Bias of Calcification Analyzed by vascuCAP™ Non-invasively Relative to Histopathology as Ground Truth. — -0.47; .07 mm2

Primary: Changing LDL Cholesterol — 100; 70 Mg/dl

Primary: Annualized LRNC Volume Change in Carotid Plaque Composition, as Assessed by MRI — -4.6; -15.1; -9.4 mm^3/year

Primary: Percent Change in Atheroma Volume (PAV) in the Thoracic Aorta of Spironolactone vs. Placebo — 0.5; 7.3 percentage change — p=0.0293

Primary: C-Reactive Protein (CRP) — 3.7; 4.6 mg/L

Primary: Number of Participants With Adverse Events, Serious Adverse Events and Death — 80; 77; 14; 25 Number of participants

Primary: Evidence of Carotid Artery or Intracranial Artery Atherosclerosis Confirmed by Vascular Ultrasonography — 96; 1063; 826; 241 artery numbers

Primary: Change in Carotid Intima-media Thickness From Baseline to Year 1 — 0.766; 0.765; 0.758; 0.768 millmeter — p=0.7279

Primary: Major Adverse Events (MAEs) Within 30 Days — 2 Participants

Primary: Flow-mediated, Endothelium-dependent Vasodilation — 6.8; 8.7 percentage vasodilation

Primary: Brachial Artery Vascular Function — 5.1; 3.1; 4.4 percent vasodilation

Primary: Change in the Mean Vessel Wall Area (VMA) of the Carotid Bulb From Baseline to 2 Years — -6.7; 3.4 mm2

Primary: Change of Subclavian Flow to Normal Flow Pattern During Cuff Test — 0; 2 participants

Primary: Change From Baseline in Percent Atheroma Volume(PAV) After 104 Weeks of Treatment — -0.33; 0.11 percentage of baseline

Primary: Progression Rates of Low Attenuation Plaque Under Influence of Vascepa as Compared to Placebo as a Change Between Two or More Time Points — -0.3; 0.9 volume in mm cubed

Primary: Change in Mean of Wall Volume of Internal Carotid Arteries — -3.52; -5.91 Other - mm^3 ( cubic millimeter )

Primary: Change in Necrotic Core Volume — 0.07 mm^2

Primary: Mean Fold Change in Brachial Vein Endothelial Inflammatory Transcript — 8.6; 2.8 Fold Change

Primary: Change in Nitric Oxide Formation From Baseline to 3 Months. — 10.0; 11.2; 10.0; 11.0 ng/mL

Primary: Stroke or Death in the Territory of Qualifying Artery — 5 Participants — p=0.08

Primary: Change From Baseline in Common Carotid Artery Intima-Media Thickness (IMT) — 0.877; 0.879; 0.036; 0.033 mm

Primary: Fatal and Nonfatal Ischemic Stroke in the Vertebrobasilar Territory — 72 Participants

Primary: Number of Patients in Which Platelet Activity Measurements Were Associated With Short-term Cardiovascular Events — 31; 16 participants

Primary: Endothelial Function — 0.13; -0.04 reactive hypermia index

Primary: Time to Hemostasis (TTH) — 5.87 minutes

Primary: Percent Change in Flow Mediated Dilatation (FMD) — -0.39; -0.07; -0.08 post-occlusion diameter change as % — p=0.238

Primary: Lower Extremity Skeletal Muscle Glucose Uptake — 62.9; 48.6; 49.5 umol/kg/min

Primary: Percent Cross-sectional Area of Macrophages in Plaque Tissue — 8.08; 8.19 Percent Area — p=0.97

Primary: Safety Endpoint: Number of Participants With Freedom From Major Adverse Events — 110 Participants

Primary: Number of Major Adverse Cardiac Events (MACE) — 9; 6; 2; 119 Participants